The NCI's Scientific Program Leaders and Board of Scientific Advisors have approved the continuation of NCI’s Cancer Nanotechnology
Program for another 5 year period with initial awards to be made in September 2015.
The components of the program will be funded through following announcements:
Centers of Cancer Nanotechnology Excellence (U54) with set aside of $12-13M/year for 5-6 CCNEs.
Cancer Nanotechnology Research Platforms (U01). There will be multiple receipt dates for this Announcement.
Nanotechnology Research Training Programs (T32) supported with designated funds of $2M/year for five years. Proposals will be received through PA-14-015, with 1st receipt date of September 25, 2014.

Learn more about the Alliance's current programs and other research funding opportunities.

For more information about the Alliance, please contact:
NCI Office of Cancer Nanotechnology Research (OCNR)
National Cancer Institute
Center for Strategic Scientific Initiatives
Building 31, Room 10A52
31 Center Drive, MSC 2580
Bethesda, MD 20892-2580
Telephone: (301) 451-8983

For information on NCI clinical trials now accepting participants, please visit: or contact the NIH Clinical Center directly at 1-888-NCI-1937 (1-888-624-1937) to be connected to a referral coordinator appropriate for your diagnosis. For media inquiries, please contact:
NCI Press Officers
Phone: (301) 496-6641
Fax: (301) 451-7440
For general information or to seek help, please visit: or call NCI's Cancer Information Services at
1-800-4-CANCER (1-800-422-6237)

Recent publications of Nanotechnology in Cancer

Perspectives and potential applications of nanomedicine in breast and prostate cancer.
Liu Y, Solomon M, Achilefu S. Med Res Rev. 2013 Jan;33(1):3-32. doi: 10.1002/med.20233. Epub 2010 Nov 9. Review.

Using functional nanomaterials to target and regulate the tumor microenvironment: diagnostic and therapeutic applications.
Ji T, Zhao Y, Ding Y, Nie G. Adv Mater. 2013 Jul 12;25(26):3508-25. doi: 10.1002/adma.201300299. Epub 2013 May 24. Review.

Nanotechnological selection.
Demming A. Nanotechnology. 2013 Jan 18;24(2):020201. doi: 10.1088/0957-4484/24/2/020201. Epub 2012 Dec 14.

Multifunctional superparamagnetic iron oxide nanoparticles: promising tools in cancer theranostics.
Santhosh PB, Ulrih NP.. Cancer Lett. 2013 Aug 9;336(1):8-17. doi: 10.1016/j.canlet.2013.04.032. Epub 2013 May 7. Review.

Near-infrared light-mediated nanoplatforms for cancer thermo-chemotherapy and optical imaging.
Zhang Z, Wang J, Chen C. Adv Mater. 2013 Jul 26;25(28):3869-80. doi: 10.1002/adma.201301890. Epub 2013 Jun 6. Review.

Emerging applications of nanomedicine in dermatology.
Saraceno R, Chiricozzi A, Gabellini M, Chimenti S. Skin Res Technol. 2013 Feb;19(1):e13-9. doi: 10.1111/j.1600-0846.2011.00601.x. Epub 2011 Dec 18. Review.

Nanooncology: the future of cancer diagnosis and therapy.
Thakor AS, Gambhir SS. CA Cancer J Clin. 2013 Nov-Dec;63(6):395-418. doi: 10.3322/caac.21199. Epub 2013 Oct 1. Review.

Identification and usage of fluorescent probes as nanoparticle contrast agents in detecting cancer.
Murahari MS, Yergeri MC. Curr Pharm Des. 2013;19(25):4622-40. Review.

Recent progress in nanomedicine: therapeutic, diagnostic and theranostic applications.
Rizzo LY, Theek B, Storm G, Kiessling F, Lammers T.Curr Opin Biotechnol. 2013 Dec;24(6):1159-66. doi: 10.1016/j.copbio.2013.02.020. Epub 2013 Apr 9. Review.

Nanotheranostics of circulating tumor cells, infections and other pathological features in vivo.
Kim JW, Galanzha EI, Zaharoff DA, Griffin RJ, Zharov VP.Mol Pharm. 2013 Mar 4;10(3):813-30. doi: 10.1021/mp300577s. Epub 2013 Feb 25. Review. PMID: 23379366 [PubMed - indexed for MEDLINE] Free PMC Article

Targeted therapy using nanotechnology: focus on cancer.
Sanna V, Pala N, Sechi M. Int J Nanomedicine. 2014 Jan 15;9:467-83. doi: 10.2147/IJN.S36654. eCollection 2014. PMID: 24531078 [PubMed - in process] Free PMC Article

Nanoarchitectonics in cancer therapy and imaging diagnosis.
Pandey AP, Girase NM, Patil MD, Patil PO, Patil DA, Deshmukh PK. J Nanosci Nanotechnol. 2014 Jan;14(1):828-40. Review.